Live Chat ×
Skip to main content

A New Era in Reducing Treatment Burden in Retinal Disease - Saturday, November 14, 2020


A New Era in Reducing Treatment Burden in Retinal Disease

CME Symposium

Saturday, November 14, 2020
5:30 AM PST | 6:30 AM MST | 7:30 AM CST | 8:30 AM EST

Please click the REGISTER button on the right to register for this program. You will receive a confirmation email with a link to access the program. A reminder email closer to the date of the program will be sent as well.

If you would like to register for other AAO MedEdicus CME Programs: 

Please contact with any questions. Thank you!


Peter K. Kaiser, MD (Chair)
Chaney Family Endowed Chair in Ophthalmology Research
Professor of Ophthalmology
Cole Eye Institute
Cleveland Clinic Lerner College of Medicine
Cleveland, Ohio 

Sophie J. Bakri, MD
Professor of Ophthalmology
Mayo Clinic
Rochester, Minnesota
Nancy M. Holekamp, MD
Professor of Clinical Ophthalmology
Washington University School of Medicine
Director, Retina Services
Pepose Vision Institute
St Louis, Missouri

Arshad M. Khanani, MD, MA
Managing Partner
Director of Clinical Research
Director of Fellowship
Sierra Eye Associates
Clinical Associate Professor
University of Nevada, Reno School of Medicine
Reno, Nevada


Target Audience
This educational activity is intended for retina specialists and other ophthalmologists managing retinal disease.

Learning Objectives
After completing this activity, participants will be better able to:
  • Describe the different mechanisms of extended therapeutic effect for investigational and current treatments for retinal diseases
  • Interpret clinical trial data for approved and emerging treatments for retinal diseases
  • Develop individualized treatment plans for patients with nAMD that optimize both treatment burden and long-term VA gains
  • Integrate treatment strategies into practice that maximize visual acuity gains and minimize treatment burden

Accreditation Statement
MedEdicus is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
MedEdicus designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Obtaining Credit
To obtain AMA PRA Category 1 Credit ™ for this activity, participate in the meeting, consult referenced sources as necessary, and complete the posttest and evaluation online. After completing the posttest and evaluation, a certificate will be made available immediately.

Disclosure Policy
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.

Sophie J. Bakri, MD, is a consultant for Adverum, Alimera Sciences, Allegro Ophthalmics, LLC, Allergan, Apellis Pharmaceuticals, F. Hoffmann-La Roche Ltd, Genentech, Inc, Kala Pharmaceuticals, Novartis Pharmaceuticals Corporation, and Oxurion.

Nancy M. Holekamp, MD, receives intellectual rights/is a patent holder of Katalyst Healthcares & Life Sciences; is a consultant for AbbVie Inc, Acucela Inc, Allergan, Apellis Pharmaceuticals, Clearside Biomedical, Inc, Gemini Therapeutics, Genentech, Inc, Gyroscope, Ionic Biomedical, Inc, Katalyst Healthcares & Life Sciences, Nacuity Pharmaceuticals, Inc, Notal Vision, Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals, Inc; is on the speakers bureau for Allergan, Genentech, Inc, Regeneron Pharmaceuticals, Inc, and Spark Therapeutics, Inc; is a contracted researcher for Gemini Therapeutics, Genentech, Inc, Gyroscope, Notal Vision, and Regeneron Pharmaceuticals, Inc; and has ownership interest in Katalyst Healthcares & Life Sciences.

Peter K. Kaiser, MD, is a consultant for Aerie Pharmaceuticals, Inc, Alcon, Allegro Ophthalmics, LLC, Allergan, Alzheon, Inc, Annexon Inc, AsclepiX, Bausch & Lomb Incorporated, Bayer Corporation, bioeq GmbH, Biogen Idec, Bionic Vision Technologies, Boehringer Ingelheim International GmbH, Carl Zeiss Meditec, Inc, Chengdu Kanghong Pharmaceutical Group Co Ltd, Clearside Biomedical, Inc, DTx Pharma, Duet Therapeutics, Eyevensys, Formycon AG, Galecto Biotech, Galimedix Therapeutics, Inc, Gemini Therapeutics, Glaukos Corporation, Innovent Biologics, Inc, iRenix, IVERIC bio, jCyte, Kala Pharmaceuticals, Kanaph Therapeutics, Kodiak Sciences Inc, NGM Biopharmaceuticals, Novartis Pharmaceuticals Corporation, Ocugenix, Oculis, Ocuphire Pharma, OcuTerra Therapeutics Inc, Omeros Corporation, Opthea, Oxurion NV, Palatin Technologies, Inc, Regeneron Pharmaceuticals, Inc, Regenxbio Inc, Retinal Sciences, Retrotope Inc, Roivant Sciences Ltd, Sandoz International GmbH, Santen Inc, Spark Therapeutics, Inc, Stealth BioTherapeutics Inc, Sustained Nano Systems, LLC, Takeda Pharmaceuticals USA, Inc, and Thea Pharmaceuticals Limited; is on the speakers bureau for Novartis Pharmaceuticals Corporation; and has ownership interest in Allegro and IvericBio.

Arshad M. Khanani, MD, MA, is a consultant for Adverum, Allergan, Bausch & Lomb Incorporated, Chengdu Kanghong Pharmaceutical Group Co Ltd, EyePoint Pharmaceuticals, Genentech, Inc, Gyroscope, Gemini Therapeutics, GrayBug, Inc, Novartis Pharmaceuticals Corporation, Opthea, Oxurion NV, PolyPhotonix, Recens Medical, Inc, and Regenxbio Inc; is on the speakers bureau for Allergan and Novartis Pharmaceuticals Corporation; and is a contracted researcher for Adverum, Allergan, Chengdu Kanghong Pharmaceutical Group Co Ltd, Gemini Therapeutics, Genentech, Inc, Gyroscope, GrayBug, Inc, Novartis Pharmaceuticals Corporation, Opthea, Oxurion NV, PolyPhotonix, Recens Medical, Inc, and Regenxbio Inc.

Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.

Disclosure of Commercial Support
This continuing medical education activity is supported through an unrestricted educational grant from Allergan.

Off-Label Discussion

This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at


The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Allergan.

This CME activity is copyrighted to MedEdicus LLC © 2020. All rights reserved. 229

This CME symposium is not affiliated with the official program of AAO 2020.

November 14, 2020
Sat 8:30 AM EST

Duration 1H 30M

Already Registered?